Findings from the recent cardiovascular outcome trials have demonstrated that SGLT2 inhibitors reduced hospitalization for HF by 27–35% in patients with T2DM with or without CVD and with or without a history of HF (5–7). This evidence concerns the gene SLC5A2 and hydrops fetalis.